期刊文献+

血管内皮生长因子在分化型甲状腺癌中的表达及意义 被引量:3

Expression of serum vascular endothelial growth factor in differentiated thyroid cancer
原文传递
导出
摘要 目的观察血管内皮生长因子(vascular endothelial growth factor,VEGF)在分化型甲状腺癌(differentiated thyroid carcinoma,DTC)患者手术前后及复发时血清中的表达及其与血清甲状腺球蛋白(thyroglobulin,Tg)浓度之间的关系。方法采用酶联免疫吸附法(enzymelinked immunosorbentassay,ELISA)检测30例OTC(术后肺转移7例、局部复发23例)在术前、术后及复发时血清VEGF(serumVEGF,sVEGF)的水平及化学发光法检测血清Tg及TgA的浓度,并与30例正常对照组比较。结果肺转移组及局部复发组在手术前sVEGF比较差异无统计学意义(t=0.373,P〉0.05),与对照组比较差异有统计学意义(t值分别为8.597、14.140,P均〈0.05);肺转移组及局部复发组在术后sVEGF明显降低,与术前比较差异有统计学意义(t值分别为5.977、11.500,P均〈0.05);术后2组sVEGF与对照组比较差异均无统计学意义(t值分别为1.593、1.525,P均〉0.05);肺转移组及局部复发组在复发前后sVEGF比较差异有统计学意义(t值分别7.387、12.160,P均〈0.05),复发后肺转移组sVEGF较局部复发组明显增高,差异亦有统计学意义(t=4.167,P〈0.05)。2组血清瞻浓度与sVEGF表达成直线正相关(r=0.786,P〈0.01)。结论sVEGF在DTC术前及术后复发患者血清中高表达,可作为评估DTC生物学行为的一项重要指标。 Objective To evaluate the expression of serum vascular endothelial growth factor(sVEGF) in differentiated thyroid carcinoma(DTC) patients before and after thyroidectomy and when recurrence occured. To analyze the relationship between serum VEGF and serum thyroglobulin(Tg)level. Methods sVEGF levels of 30 cases of DTC(7 patients with pulmonary metastasis, 23 patients with locoregional recurrence)were determined by enzyme-linked immunosorbent assay(ELISA) before and after thyroidectomy and when recurrence occured. The levels of serum Tg and thyroglobulin antibodies (TgA)were detected by chemiluminescence method. The results were compared with those of the 30 cases of normal controls. Results sVEGF levels had no significant difference between pulmonary metastasis group and locoregional recurrence group before operation ( t = 0. 373, P 〉 0.05 ), but they were significantly higher than those in the normal control group( t = 8. 597 and 14. 14 respectively, all P 〈 0. 05). sVEGF levels in patients with pulmonary metastasis or locoregional recurrence were significantly reduced at the 3^rd week after operation and the difference had statistical significance with those before operation( t = 5. 977, 11.50, P 〈 0. 05). The difference of postoperative level of sVEGF in patients with pulmonary metastasis, locoregional recurrence and in patients of normal control group had no statistical significance ( t = 1. 593,1. 525, P 〉 0. 05). sVEGF levels in patients with pulmonary metastasis or locoregional recurrence were significantly higher after recurrence than those before recurrence( t = 7. 387, 12. 16 ,P 〈 0. 05). After recurrence sVEGF levels in patients with pulmonary metastasis were significantly higher than those in patients with locoregional recurrence (t = 4. 167, P 〈 0. 05) It showed a positive linear correlation between serum Tg level and sVEGF level in DTC patients with recurrence(r =0. 786,P 〈0. 01 ). Conclusion sVEGF is significantly elevated in DTC patients before operation and with postoperative recurrence, making it an important indicator to reveal the biological behaviors of DTC.
出处 《中华内分泌外科杂志》 CAS 2013年第4期269-271,共3页 Chinese Journal of Endocrine Surgery
基金 基金项目:山东省2009年科技攻关项目(2009GG20002085)
关键词 分化型甲状腺癌 血管内皮生长因子 转移 复发 Differentiated thyroidcarcinoma Vascular endothelial growth factor Metastasis Recurrence
  • 相关文献

参考文献4

  • 1Yang ZF, Ho DW, Lau CK, et al. Allograft inflammatory factor-1 ( AIF-1 ) is crucial for the survival and pro-inflammatory activity of maerophages[ J]. Int Immunol, 2005,17 ( 11 ) : 1391-1397.
  • 2张建伟,王军,魏温涛.VEGF和VEGF-C在甲状腺癌组织中的表达与临床病理特征的关系[J].兰州大学学报(医学版),2007,33(3):1-3. 被引量:4
  • 3Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular en- dothelial growth factor(VEGF) and VEGF-C levels as tumor mark- ers in patients with cervical carcinoma [ J ]. Cancer, 2005, 103 (4) : 724-730.
  • 4Klein M, Picard E, Vignand JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma[ J]. J Endocrinol, 1999,161 (1) :41-49.

二级参考文献2

共引文献3

同被引文献69

  • 1张建伟,王军,魏温涛.VEGF和VEGF-C在甲状腺癌组织中的表达与临床病理特征的关系[J].兰州大学学报(医学版),2007,33(3):1-3. 被引量:4
  • 2徐静,李婷婷,陈光,等.1018例甲状腺癌临床病理学分析[J].中华普外科杂志,2011,4(26):279-282.
  • 3De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline [ J]. J Clin Endocnnol Metab, 2012, 97(8) : 2543-2565.
  • 4Neil D. Gross. Pregnant patient with thyroid nodule[ R]. Ameri- can Acadeny of Otolaryngology. Head and Neck Surgery, 2010, 40(3) : 1-24.
  • 5Rosen IB, Korman M, Walfish PG. Thyroid nodular disease in pregnancy: current diagnosis and management [ J]. Clin Obstet Gynecol, 1997, 40(1) : 81-89.
  • 6Zoona S, Mahmood S. Cancer in pregnancy[ J]. Obstetrics, Gy- naecology and Reproductive medicine, 2011 : 183-189.
  • 7Smith LH, Danielsen B, Allen ME, et al. Cancer associated with obstetric delivery: results of linkage with California cancer registry [J]. Am J Obstet Gwlecol. 2003. 189(4) : 1128-1135.
  • 8Davies L, Welch HG. Increasing incidence of thyroid cancer in the U- nited States, 1973-2002 [J]. JAMA, 2006, 295(18) :2164-2167.
  • 9Brindel P, Doyon F, Rachedi F, et al. Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in native women in French Polynesia: a population-based case-control study [J]. AmJEpidemiol, 2008, 167(2): 219-229.
  • 10Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hm'mone level in thyroid nodule patients is asso- ciated with greater risks of differentiated thyroid cancer and ad- vanced tmnor stage[J]. J Clin Endocrinol Metab, 2008, 93 (3): 809-814.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部